Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 24%
Buy 18%
Hold 53%
Sell 6%
Strong Sell 0%

Bulls say

Zimmer Biomet Holdings is a leading player in the orthopedic reconstructive implant market, with a strong presence across the US, Europe, and Japan through its recent acquisitions. While the company has divested its dental and spine businesses, its core focus on orthopedic implants positions it well to capture market share as demand for joint replacement surgeries continues to grow. The recent transition to a direct-sales model may cause some short-term disruption, but the company's strong fundamentals, including its robust product portfolio and continued investment in innovation, make it a solid long-term investment.

Bears say

Zimmer Biomet Holdings is facing headwinds in its core orthopedic arena due to pricing pressure and potential challenges with new product launches. Additionally, the company's significant exposure to international markets leaves it vulnerable to changes in market dynamics. While its acquisition of Paragon 28 has been a positive driver of growth, success in expanding its product portfolio will be crucial in driving sustainable growth and closing the valuation gap with peers.

ZBH has been analyzed by 17 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 18% recommend Buy, 53% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 17 analysts, ZBH has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.